Tag: targeted therapy for RET mutations

Home / targeted therapy for RET mutations

Categories

Pralsetinib is approved by the FDA for non-small cell lung cancer with RET gene fusions

August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (N...
targeted-therapy-for-ret-mutations

Scan the code